Business Management Articles

Keeping a Tight Rein on Unnecessary Expenditures in Oncology Practice
Doctors from Intermountain Healthcare decided to see if they could improve outcomes of patients placed on expensive machines.
The FDA has approved Lutathera for the treatment of patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. 
Fewer than 4% of patients with cancer in the United States participate in clinical trials, the elderly and individuals with clinically relevant comorbidities are strikingly underrepresented in the research portfolio.
The debate continues to rage over whether the difference in the cost of oncologic care between outpatient hospital and physician private offices is appropriate.
Kathryn F. Mileham, MD, discusses the development of biomarker testing for patients with mutated non-small cell lung cancer.
Precision Medicine Can Help Reduce
In patients with common solid tumors, it is well-established that those with early-stage cancers have a statistically defined superior prognosis compared with those who present with and are required to be treated at later stages of the disease.
Despite the widespread availability of antiemetic regimens, between 30% and 50% of patients receiving chemotherapy experience treatment-related nausea and/or vomiting.
There are certain commonly used terms in the realm of oncology that may result in unintended consequences and should be considered carefully before being employed in conversation or in writing.
More than 2 years after the passage of the Medicare Access and CHIP Reauthorization Act of 2015, the progression toward value-based care has challenged oncologists to assume an unprecedented degree of accountability for the well-being and holistic care of their patients.
Congressional "right-to-try" legislation could make investigational drugs available to desperately ill patients sooner in the trials process, but there are substantial risks.
Publication Bottom Border
Border Publication